Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study. Abramson JS, Siddiqi T, Gordon LI, Lunning M, et al. Blood 2026;148:1388-1393.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Abramson JS, Siddiqi T, Gordon LI, Lunning M, et al. Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study. Blood 2026;148:1388-1393.
PMID: 42237652